Open Access

TlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines

  • Authors:
    • Qiaomei Dai
    • Yaozhang Li
    • Meiqiao Wang
    • Yang Li
    • Ji Li
  • View Affiliations

  • Published online on: February 26, 2020     https://doi.org/10.3892/etm.2020.8557
  • Pages: 3009-3016
  • Copyright: © Dai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Asarinin is one of the main active chemical components isolated from Xixin, a Chinese medicine. To investigate the role of asarinin in rheumatoid arthritis (RA), the present study investigated the effect of an asarinin‑medicated serum on human fibroblast‑like synoviocytes in vitro. An asarinin‑medicated serum was generated and analyzed by high‑performance liquid chromatography. Fibroblast‑like synoviocytes were isolated from patients with osteoarthritis and RA. The third generation of the rheumatoid synoviocytes was used in the experimental research and the third generation of osteoarthritic synoviocytes was used as control cells. Trypan blue staining was performed to detect the viability of RA synovial fibroblasts (RASFs). ELISA, reverse transcription‑quantitative (RT‑q) PCR and western blotting were also performed to detect the expression of various cytokines. Additionally, RT‑qPCR was employed to detect Toll‑like receptor (TLR) 2 and TLR4. The results revealed that medicated asarinin serum inhibited the viability of RASFs in a dose‑ and time‑dependent manner. The serum also suppressed the expression of interleukin (IL)‑17A, tumor necrosis factor‑α, interferon‑γ, IL‑6, TLR2 and TLR4. The inhibitory effect of asarinin drug serum on RASFs may be achieved by inhibition of T helper cell (Th)1/Th17 cytokines through suppression of TLR2 and TLR4.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 19 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dai Q, Li Y, Wang M, Li Y and Li J: TlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines. Exp Ther Med 19: 3009-3016, 2020
APA
Dai, Q., Li, Y., Wang, M., Li, Y., & Li, J. (2020). TlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines. Experimental and Therapeutic Medicine, 19, 3009-3016. https://doi.org/10.3892/etm.2020.8557
MLA
Dai, Q., Li, Y., Wang, M., Li, Y., Li, J."TlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines". Experimental and Therapeutic Medicine 19.4 (2020): 3009-3016.
Chicago
Dai, Q., Li, Y., Wang, M., Li, Y., Li, J."TlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines". Experimental and Therapeutic Medicine 19, no. 4 (2020): 3009-3016. https://doi.org/10.3892/etm.2020.8557